Submitted by Anonymous (not verified) on 23 November 2023 - 13:21
Human medicines European public assessment report (EPAR): Herwenda, trastuzumab, Breast Neoplasms;Stomach Neoplasms, Date of authorisation: 15/11/2023, Status: Authorised
Source: